

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for rituximab products under the patient's prescription drug benefit.

Description:

This is a regulatory policy for rituximab products applicable to the state of Maryland.

Applicable Drug List:

Riabni Rituxan Ruxience Truxima

Policy/Guideline:

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections

Authorization may be granted when the patient has a diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.

Pediatric acute onset neuropsychiatric syndrome

Authorization may be granted when the patient has a diagnosis of pediatric acute onset neuropsychiatric syndrome.

Autoimmune encephalitis

Authorization may be granted when the patient has a diagnosis of autoimmune encephalitis.

Approval Duration and Quantity Restrictions:

Approval: 6 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

AETNA BETTER HEALTH®



Coverage Policy/Guideline

ooverage i oliey, dalaeline				
Name:	Rituximab Products		Page:	2 of 2
Effective Date: 7/3/2025 Last Review Date: 6/2025				Date: 6/2025
Applies to:	□Illinois	□Florida	□F	lorida Kids
	□New Jersey	⊠Maryland	\boxtimes V	'irginia
	🗆 Pennsylvania Kids	□Pennsylvania	□K	entucky PRMD

References:

- 1. Maryland Senate Bill 475. May 2020.
- 2. Maryland House Bill 820. May 2022.
- 3. Virginia H 1641. March 2025.